New study has revealed that supercharging the mutation rate in cancer cells could create a “powerful vaccine” that is able to boost the effectiveness of immunotherapy. The international study, which was carried out by scientists at The Institute of Cancer Research, London, the Mayo Clinic in Rochester, US, and the University of Leeds, forced cancer
A new handheld 3D printer can deposit sheets of skin to cover large burn wounds and its “bio-ink” can increase the healing process. Developed by a team of researchers from the University of Toronto Engineering and Sunnybrook Hospital, the device covers wounds with a uniform sheet of biomaterial, stripe by stripe. The bio-ink dispensed by
A new type of scan that involves magnetising molecules allows doctors to see in real-time which regions of a breast tumour are active. Meaning that researchers can, for the first time, demonstrated that carbon-13 hyperpolarised imaging, can be used to monitor breast cancer. The team based at the Cancer Research UK Cambridge Institute and the
Scientist have announced that a newly discovered part of the human immune system could be harnessed to treat all cancers. The Cardiff University team discovered a method of killing prostate, breast, lung and other cancers in lab tests. Although the findings (published in Nature Immunology) have not been tested in patients, but the researchers say
MSD announces worldwide research collaboration and license agreement with Taiho Pharmaceutical and Astex Pharmaceuticals, both subsidiaries of Otsuka, to develop small molecule inhibitors against several drug targets. It was revealed that the partnership intends to investigate drugs including the KRAS oncogene, which are currently being investigated for the treatment of cancer. KRAS is among the
Scientific Professionals, part of the Clinical Professionals Group would like to wish everyone a Merry Christmas and a Happy New Year. Scientific Professionals offices will be closed from on the 25th of December and will reopen on Thursday 2nd January. We are proud to say that Scientific Professionals has had a fantastic and eventful year!
Amgen, after the acquisition of Nuevolution and its world-class DNA-encoded library (DEL) platform, Amgen has a team of expert’s adept at making and screening billions to trillions of compounds to find promising leads. The huge increase in screening power will fuel Amgen’s search for bispecific small molecules that use the body’s cellular machinery to tackle
AstraZeneca and Novoheart are collaborating on developing a functioning miniature human heart model of heart failure, a first of its kind. The ‘heart-in-a-jar’, Novoheart’s proprietary 3D human ventricular cardiac organoid chamber (hvCOC) technology, will be made from human stem cells and will replicate the key characteristics of heart failure. This will include preserved ejection fraction
Hertfordshire Local Enterprise Partnership announced plans to invest an extra £1.2 million into Stevenage Bioscience Catalyst (SBC), in order to “help grow a world-class cell and gene therapy cluster.” The money will help reinforce the campus as a world class cell and gene therapy cluster, providing much-needed temporary accommodation for growing companies of that nature.
Oxford Drug Design (ODD) has won a UK-China antimicrobial resistance grant, in addition to also boosting its funding with investment from the Angel CoFund. Oxford Drug Design Limited has raised a combined £2.2m in funding from the Angel CoFund (ACF), o2h Ventures and other new investors. Whilst also gaining grant funding from the UK Department